Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.62 |
| ▸ | FLT1 | P17948 | 4/20 | 0.44 |
| ▸ | VEGFA | P15692 | 4/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921336 | 0.77 | EGLN1 (1.00) | EGLN1FLT1VEGFAEGLN3FTO | |
| SCHEMBL24405275 | 0.75 | EGLN1 (0.73) | EGLN1FLT1VEGFAEGLN3 | |
| SCHEMBL24405146 | 0.72 | EGLN1 (0.54) | EGLN1FLT1VEGFAEGLN3FTO | |
| SCHEMBL12896107 | 0.70 | EGLN1 (0.46) | EGLN1ACACBACACAPOLB | |
| SCHEMBL24405086 | 0.67 | EGLN1 (0.48) | EGLN1FLT1VEGFAEGLN3 | |
| SCHEMBL19676830 | 0.66 | EGLN1 (0.58) | EGLN1FLT1VEGFAEGLN3MAP4K4 | |
| SCHEMBL25777345 | 0.66 | EGLN1 (0.73) | EGLN1FLT1VEGFAEGLN3FTO | |
| SCHEMBL29721769 | 0.65 | EGLN1 (0.65) | EGLN1FLT1VEGFAEGLN3FTO | |
| SCHEMBL21444651 | 0.65 | EGLN1 (0.59) | EGLN1FLT1VEGFAEGLN3FTO | |
| SCHEMBL28789351 | 0.65 | EGLN1 (0.65) | EGLN1FLT1VEGFAEGLN3FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357911-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3323807-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |